Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03301454 | Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic…(E-DIS2) | Phase 2 | terminated | Oct 4, 2017 | Centre Oscar Lambret | This decision was taken on June 20 2022 due to low recruitment over the past 4 years. | Enrollment / accrual |
| NCT06181201 | Association Between the Composition of the Intestinal Microbiota and Tumor Response in…(Neo-Flo-Rect) | — | terminated | Dec 26, 2023 | Centre Oscar Lambret | Lack of eligible patients | Other (stated, no rule matched) |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and…(ALAFOSS-01) | Phase 1 | terminated | Sep 19, 2024 | AstraZeneca | The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01… | Enrollment / accrual |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word… | N/A | terminated | May 8, 2015 | Centre Oscar Lambret | Lack of patient enrollment | Enrollment / accrual |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative…(NeuroPrevPTSD) | Phase 2 | terminated | Aug 29, 2018 | Centre Oscar Lambret | Lack of recruitment and of study staff | Enrollment / accrual |
| NCT07137390 | A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With… | Phase 1 / Phase 2 | withdrawn | Aug 22, 2025 | M.D. Anderson Cancer Center | 0 participants enrolled | Enrollment / accrual |
| NCT04166383 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | Phase 2 | terminated | Nov 18, 2019 | National Cancer Institute (NCI) | Interim analysis indicated limited efficacy | Efficacy / futility |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | Phase 3 | terminated | Mar 2, 2021 | Translational Research in Oncology | The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve… | Enrollment / accrual |
| NCT00748449 | Colonography Versus Colonoscopy in High Risk Patient(COLO-TDM) | N/A | terminated | Sep 8, 2008 | Assistance Publique - Hôpitaux de Paris | No more inclusions | Other (stated, no rule matched) |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With…(MAST) | Phase 1 | terminated | Apr 26, 2022 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT06281925 | Cryotherapy & Oxaliplatin | N/A | suspended | Feb 28, 2024 | NYU Langone Health | Study paused to enrollment | Enrollment / accrual |
| NCT06292975 | Exercise for Improving Radiotherapy Efficacy in Rectal Cancer | N/A | withdrawn | Mar 5, 2024 | University of Hull | Although patients were screened, only two met the eligibility criteria within the available… | Enrollment / accrual |
| NCT04327700 | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | Phase 2 | terminated | Mar 31, 2020 | Wake Forest University Health Sciences | Slow accruals | Enrollment / accrual |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the… | Phase 1 / Phase 2 | terminated | Mar 5, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT07223567 | A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing… | Phase 2 | withdrawn | Nov 3, 2025 | M.D. Anderson Cancer Center | 0 participants enrolled | Enrollment / accrual |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary… | Phase 2 | terminated | Dec 24, 2018 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT05983367 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in… | Phase 2 | terminated | Aug 9, 2023 | Inspirna, Inc. | At the time of the primary analysis, results did not meet the primary endpoint | Other (stated, no rule matched) |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic… | Phase 1 | terminated | Feb 10, 2022 | Pfizer | Study terminated based on internal business considerations and was not based on safety reasons | Safety / toxicity |
| NCT06603818 | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in… | Phase 2 | withdrawn | Sep 19, 2024 | National Cancer Institute (NCI) | The trial is closing due to findings from a related study, prompting the sponsor to discontinue… | Other (stated, no rule matched) |
| NCT06217094 | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 | withdrawn | Jan 22, 2024 | University of Florida | funding terminated | Funding |
| NCT06851104 | A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With… | Phase 2 | terminated | Feb 28, 2025 | Guangxi Medical University | The support from the relevant company was not obtained as planned | Sponsor / business decision |
| NCT02738606 | Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver… | Phase 2 | terminated | Apr 14, 2016 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With… | Phase 1 / Phase 2 | withdrawn | Apr 5, 2022 | Institut de Recherches Internationales Servier | Strategic development reasons | Sponsor / business decision |
| NCT05442749 | Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic…(PARPi-PANC) | Phase 2 | terminated | Jul 5, 2022 | Centre Leon Berard | Study not feasible, patient accrual rate too low. | Enrollment / accrual |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT03065062 | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR… | Phase 1 | suspended | Feb 27, 2017 | Dana-Farber Cancer Institute | Funding and drug supply to continue the study are pending. | Drug supply |
| NCT05360745 | Quality of Life With Nutritional Supplementation in Patients With Locally…(FOODPANC) | N/A | withdrawn | May 4, 2022 | Fundacion para la Excelencia y la Calidad de la Oncologia | Few months later the site initiation visit, the principal investigator decided not to continue with… | Investigator |
| NCT06501989 | Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer | Phase 2 | withdrawn | Jul 15, 2024 | Inova Health Care Services | Principal Investigator has left Inova | Investigator |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT07323576 | A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in…(INAVO-CRC) | Phase 2 | withdrawn | Jan 7, 2026 | Hoffmann-La Roche | Sponsor's decision | Sponsor / business decision |
| NCT02724202 | Curcumin in Combination With 5FU for Colon Cancer | Early Phase 1 | terminated | Mar 31, 2016 | Baylor Research Institute | PI-Initiated study; PI requested closure | Other (stated, no rule matched) |
| NCT04990895 | A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys | N/A | terminated | Aug 5, 2021 | AHS Cancer Control Alberta | Slow study accrual. Study sponsor decided to terminate the study in consultation with the DSMB. | Enrollment / accrual |
| NCT05489250 | The PLATON Network(PLATON) | — | terminated | Aug 5, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sponsor Decision | Sponsor / business decision |
| NCT05062889 | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon…(ERASE-CRC) | Phase 2 | suspended | Sep 30, 2021 | Gruppo Oncologico del Nord-Ovest | due to earlier termination of the agreement between the Sponsor and Central Laboratory for… | Enrollment / accrual |
| NCT04258566 | Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies | N/A | terminated | Feb 6, 2020 | National Institutes of Health Clinical Center (CC) | Recruitment difficulty | Enrollment / accrual |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients… | Phase 2 | terminated | Feb 17, 2023 | Replimune, Inc. | Business reasons. | Sponsor / business decision |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 19, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or… | Phase 2 | terminated | Nov 12, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT03323944 | CAR T Cell Immunotherapy for Pancreatic Cancer | Phase 1 | terminated | Oct 27, 2017 | University of Pennsylvania | Administrative reasons | Other (stated, no rule matched) |
| NCT06290856 | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced… | — | terminated | Mar 4, 2024 | Oslo University Hospital | The platform used for detecting ctDNA was not sensitive enough. | Other (stated, no rule matched) |
| NCT06457997 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Phase 1 | terminated | Jun 13, 2024 | Pheon Therapeutics | The study was terminated by Sponsor for strategic reasons. | Sponsor / business decision |
| NCT06739252 | Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA | Phase 2 | terminated | Dec 18, 2024 | Peking University | Difficulty of participants enrollment | Enrollment / accrual |
| NCT05044312 | Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative… | N/A | withdrawn | Sep 14, 2021 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory… | Phase 1 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT06006923 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | Phase 2 | terminated | Aug 23, 2023 | Anwaar Saeed | Terminated per directive from Bayer due to funding. | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Mar 23, 2026source: clinicaltrials